These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33005291)

  • 1. Notch signalling pathway in development of cholangiocarcinoma.
    Rauff B; Malik A; Bhatti YA; Chudhary SA; Qadri I; Rafiq S
    World J Gastrointest Oncol; 2020 Sep; 12(9):957-974. PubMed ID: 33005291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the Notch signaling in cholangiocarcinoma.
    Cigliano A; Wang J; Chen X; Calvisi DF
    Expert Opin Ther Targets; 2017 May; 21(5):471-483. PubMed ID: 28326864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.
    O'Rourke CJ; Matter MS; Nepal C; Caetano-Oliveira R; Ton PT; Factor VM; Andersen JB
    Hepatology; 2020 Jan; 71(1):196-213. PubMed ID: 31211856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
    Chung BK; Karlsen TH; Folseraas T
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention.
    Cadamuro M; Strazzabosco M
    Adv Cancer Res; 2022; 156():39-73. PubMed ID: 35961707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
    Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis.
    Morell CM; Fiorotto R; Fabris L; Strazzabosco M
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):447-54. PubMed ID: 23806629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling reveals potential targets in cholangiocarcinoma.
    Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
    World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.
    Khan SA; Toledano MB; Taylor-Robinson SD
    HPB (Oxford); 2008; 10(2):77-82. PubMed ID: 18773060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies.
    Limpaiboon T
    Asian Pac J Cancer Prev; 2012; 13 Suppl():41-5. PubMed ID: 23480763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
    Duwe L; Munoz-Garrido P; Lewinska M; Lafuente-Barquero J; Satriano L; Høgdall D; Taranta A; Nielsen BS; Ghazal A; Matter MS; Banales JM; Aldana BI; Gao YT; Marquardt JU; Roberts LR; Oliveira RC; Koshiol J; O'Rourke CJ; Andersen JB
    J Hepatol; 2023 Feb; 78(2):364-375. PubMed ID: 36848245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acid receptors in the biliary tree: TGR5 in physiology and disease.
    Deutschmann K; Reich M; Klindt C; Dröge C; Spomer L; Häussinger D; Keitel V
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1319-1325. PubMed ID: 28844960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of cholangiocarcinoma carcinogenesis.
    Maemura K; Natsugoe S; Takao S
    J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocarcinoma: risk factors and clinical presentation.
    Gatto M; Alvaro D
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):363-7. PubMed ID: 20496549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
    Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
    J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic alterations associated with cholangiocarcinoma (review).
    Isomoto H
    Oncol Rep; 2009 Aug; 22(2):227-32. PubMed ID: 19578760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Fluke-Associated Biliary Tract Cancer.
    Prueksapanich P; Piyachaturawat P; Aumpansub P; Ridtitid W; Chaiteerakij R; Rerknimitr R
    Gut Liver; 2018 May; 12(3):236-245. PubMed ID: 28783896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway.
    Vanaroj P; Chaijaroenkul W; Na-Bangchang K
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):551-558. PubMed ID: 36853304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholangiocarcinoma.
    Brindley PJ; Bachini M; Ilyas SI; Khan SA; Loukas A; Sirica AE; Teh BT; Wongkham S; Gores GJ
    Nat Rev Dis Primers; 2021 Sep; 7(1):65. PubMed ID: 34504109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current insights on cholangiocarcinoma research: a brief review.
    Mathema VB; Na-Bangchang K
    Asian Pac J Cancer Prev; 2015; 16(4):1307-13. PubMed ID: 25743790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.